Skip to Content

CVS, Rite Aid: Are sales of expired food and drugs a crisis or a stupid mistake?

Text SizeAAA

Filed under: Company News, Technology, Healthcare

More

On Tuesday, CVS (CVS) drugstores agreed to pay the State of New York $875,000 to settle a case alleging that it sold expired food, over-the-counter drugs, and infant formula. This settlement follows a $1.3 million settlement between New York State and Rite Aid (RAD), suggesting that this crop of expired-product sales may be just the tip of the iceberg.

This isn't the first time CVS has been cited by New York's attorney general for selling expired items. In 2003, the chain handled the problem by signing an "Assurance of Discontinuance," stating that it would "refrain from selling expired OTC drugs" and would institute "procedures to ensure that OTC drugs were identified and removed from CVS stores and directing and training employees involved in stocking of OTC drugs in these procedures."

At the time, CVS was fined $3,500: not so much a slap on the wrist as a nuzzle on the neck. No surprise that the problem would be a recurring one: Between March and May 2008, the attorney general's office discovered that 140 New York CVS stores -- 61% of the locations it inspected -- were selling expired drugs, infant formula, milk, and eggs, some more than two years past expiration.

On June 12, 2008, the attorney general's office revealed its findings to CVS and announced its intention to sue. CVS responded: "We will work aggressively to ensure that our review and removal procedures are followed consistently, in all our stores." In an inspection five days later, almost 40% of its stores were still found to be stocking expired items.

CVS responded to our inquiry about this matter with a clod of corporate boilerplate: "CVS is fully committed to maintaining inventory management practices to prevent expired products from being sold to customers. We have a comprehensive national product removal policy in place to ensure that our stores do not sell products past their expiration dates." It's not clear when CVS's "comprehensive national product removal policy" went into effect, or how it functions; director of public relations Michael DeAngelis, in an e-mail, merely cited plans to "post in-store notices reminding customers to check expiration dates."

CVS seems quite comfortable with putting its policing responsibility in the hands of its customers. The chain ran an ad in the May 2008 issue of Good Housekeeping advising readers to clear out their medicine cabinets, pointing out, "Expired products are not just ineffective but can be harmful as well." The ad urged customers to come to CVS to "replace some of the products you tossed." (DeAngelis's e-mail stated that the chain "is not aware of any consumers who were harmed by expired products that may have been sold in CVS/pharmacy stores.")

A mixed message on OTC drugs' expiration dates should come as no surprise; expired milk and eggs are one thing, but 90% of drugs retain their efficiency long after their pull dates, according to a U.S. army study. Even FDA scientists have argued that expiration dates have more to do with marketing than public safety. That gives little impetus for stores to police their OTC medications' expiration dates aggressively.

Pulling expired meds is a time-consuming, expensive process, and consumers replacing their expired or nearly expired drugs with new drugs bring lots of revenue to drugstores. So it's easy to see why CVS and Rite Aid would drag their feet on expiration compliance. In fact, the only economic impetus for spending money on expiration compliance is the threat of lawsuits and fines.

The settlements against CVS and Rite Aid help New York customers, but they don't redress expiration policing problems in other states. The issue seems to be a national one; inspectors have found similar problems with expired products in California, Pennsylvania, and New Jersey. If expiration dates really are merely a marketing tool, perhaps they need to be extended. If they're not, then it's time for the FDA to step up to the plate.

Reader Comments (Page 1 of 1)

Add your comments

Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.

When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.

To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br /> tags.

Interest Rates

5/1 ARM4.19%APR: 3.81%
30 Yr.
Fixed Mort.
5.02%APR: 5.16%
$30K
HELOC
8.00%APR: 0.00%
30 Mo
New Car Loan
6.79%APR: 0.00%
1 Yr. CD1.57%APR: 1.58%
DailyFinance Writers
Melly Alazraki Melly Alazraki Financial writer and analyst
James Altucher James Altucher Financial columnist
Jeff Bercovici Jeff Bercovici Media columnist
Jonathan Berr Jonathan Berr Financial writer and media columnist
Mercedes Cardona Mercedes Cardona Retail reporter
Tim Catts Tim Catts Financial writer
Peter Cohan Peter Cohan Author, venture capitalist and financial writer
Carrie Coolidge Carrie Coolidge Financial writer
Lita Epstein Lita Epstein Financial writer
Sam Gustin Sam Gustin Technology Writer
Nikhil Hutheesing Nikhil Hutheesing Tech and investing editor
Joseph Lazzaro Joseph Lazzaro Markets and economics writer
Latif Lewis Michelle Leder Financial Columnist
Latif Lewis Latif Lewis Business news editor and management columnist
Anthony Massucci Anthony Massucci Senior writer and tech columnist
Doug McIntyre Doug McIntyre Business and investing news writer and editor
Michael Mercurio Michael Mercurio Managing Editor
Todd Pruzan Todd Pruzan Features editor
Michael Rainey Michael Rainey Editor and economics writer
Alex Salkever Alex Salkever Senior technology writer
David Schepp David Schepp Business News reporter
Matthew Scott Matthew Scott Investing reporter and editor
Dan Solin Daniel R. Solin Author, investment advisor and retirement expert
Amey Stone Amey Stone Executive editor
Bruce Watson Mark Svenvold Columnist, renewable energy
Russel Turk, M.D. Russell Turk, M.D. Healthcare policy columnist
Bruce Watson Bruce Watson Features Writer
my portfolios

Find out why more people track their portfolios on AOL Money & Finance than anywhere else.

Create a New Portfolio My Portfolios

Daily Finance Partners

More from the Weblogs Network